Early Breast Cancer Trialists Collaborative Group, “Tamoxifen for Early Breast Cancer: An Overview of the Randomised Trials. Early Breast Cancer Trialists’ Collaborative Group,” Lancet, Vol. 351, No. 9114, 1998, pp. 1451-1467. doi:10.1016/S0140-6736(97)11423-4

has been cited by the following article:

• TITLE: Homocysteine as a Biomarker for Predicting Disease-Free Survival in Breast Cancer

  AUTHORS: Daniela Filippini Ierardi, Luis Gustavo Raimundo, Gimena Aguiar, Patrícia Bandeira Rueda Germano, Luiz Henrique Gebrim, Nelson Carvas, Bruno Frederico Aguilar Calegare, Vânia D’Almeida, Catarina Segreti Porto, Miriam Galvonas Jasiulionis, Mariangela Correa

  KEYWORDS: Homocysteine; Cysteine; Breast Cancer; Estrogen Receptor; Prognostic and Predictive Biomarker; Tamoxifen; Anastrozol

  JOURNAL NAME: Advances in Breast Cancer Research, Vol.2 No.2, April 29, 2013

  ABSTRACT: Introduction: Breast cancer is the leading cause of cancer mortality among women. Some biomarkers and clinical features are used for the diagnosis and prognosis of this tumor, but no prognostic or predictive marker is routinely available specifically for hormone receptor positive tumors. Homocysteine is well known as a risk factor in atherosclerotic vascular diseases, but its participation in cancer biology is still unclear. The aim of this study was to evaluate serum Homocysteine and Cysteine as biomarkers of disease progression in breast tumor. As a secondary objective, the effect of a short course (one month) of hormonal treatment on Homocysteine, Cysteine and DNA methylation levels was also evaluated. Methods: Blood samples, tumor samples and normal adjacent tissue were collected during the initial biopsy (pre-treatment) and after one month of hormonal therapy (post-treatment). Serum Homocysteine and Cysteine were analyzed by HPLC and tissue global DNA methylation was determined by the Methylation-Sensitive Restriction Enzyme (MSRE) technique. Results: Variations in Homocysteine levels were significantly correlated with Disease-Free Survival. Cox proportional risk model demonstrated that nodal status and Homocysteine levels were independent prognostic factors for disease-free survival (DFS). A significant difference was observed between pre-and post-treatment levels of Homocysteine and Cysteine in advanced tumors, suggesting a prognostic role in patients with poor clinical characteristics. Conclusion: Although more studies are needed to confirm these results, our research suggests that Hcy might be used as a prognostic biomarker for breast cancer.